ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial
Evandro de Azambuja
Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Related videos
17:31 Prioritising patients for breast cancer surgery during COVID-19: a surgeon's perspective
Peter Barry
7:37 Prioritising patients for breast cancer surgery during COVID-19: new treatment algorithm
Mitch Dowsett
5:01 CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
Cynthia X. Ma
2:24 DS-8201 + pembro in patients HER2+ breast and NSCLC
Sanjay Popat
2:20 Management of patients with breast cancer during COVID-19
Erin F. Cobain
